Harvard Bioscience
HBIO
78 hedge funds and large institutions have $48.7M invested in Harvard Bioscience in 2019 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 29 increasing their positions, 27 reducing their positions, and 19 closing their positions.
7% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 27
1.01% less ownership
Funds ownership: 7.48% → 6.47% (-1%)
10% less funds holding
Funds holding: 87 → 78 (-9)
37% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 19
60% less capital invested
Capital invested by funds: $121M → $48.7M (-$72.7M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ECM
Engine Capital Management
New York
|
+$5.47M |
| 2 |
DGHMC
Dalton, Greiner, Hartman, Maher & Co
New York
|
+$3.13M |
| 3 |
Millennium Management
New York
|
+$2.91M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$956K |
| 5 |
FM
Fondren Management
Houston,
Texas
|
+$905K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
-$19M |
| 2 |
BlackRock
New York
|
-$4.48M |
| 3 |
SSA
Schonfeld Strategic Advisors
New York
|
-$1.51M |
| 4 |
State Street
Boston,
Massachusetts
|
-$1.41M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$1.24M |
HBIO Hedge Fund Activity: Q2 2019 in Review
78 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Harvard Bioscience (HBIO) for Q2 2019, worth a combined $48.7M — down 60% from $121M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of HBIO and 12 opened new positions — a net loss of 7 holders — while 27 trimmed existing stakes and 29 added.
The largest buyer was Engine Capital Management, opening a new position worth an estimated $5.47M. The largest seller was First Light Asset Management, cutting an estimated $19M.
- 78 institutional investors held Harvard Bioscience (HBIO) as of Q2 2019, down from 87 in Q1 2019.
- Funds reported $48.7M of Harvard Bioscience stock for Q2 2019, down 60% quarter-over-quarter.
- 12 funds opened new Harvard Bioscience positions in Q2 2019 and 19 closed out, a net change of -7 holders.
- The largest Harvard Bioscience buyer in Q2 2019 was Engine Capital Management, an estimated $5.47M added.
- The largest Harvard Bioscience seller in Q2 2019 was First Light Asset Management, an estimated $19M sold.
Based on aggregated 13F filings for Q2 2019.